ICU Medical, Inc. (ICUI)

Over the past six months, ICU Medical's stock has experienced several events. ICU Medical announced its second-quarter 2025 results, with revenue of $548.9 million. The FDA identified a recall of ICU Medical's Plum Duo as a serious type. The company reported $2.03 earnings per share (EPS), surpassing the consensus estimate of $1.43 by $0.60. Wall Street Zen upgraded ICU Medical from a "hold" to a "buy" rating on January 19, 2026. The stock experienced daily fluctuations, with notable changes including a 4.44% increase on January 15, 2026, and a 3.70% decrease on January 23, 2026. ICU Medical is expected to release its next earnings report on February 26, 2026.

Demand for ICU Medical's products can be influenced by factors such as healthcare spending, prevalence of certain medical conditions, and hospital admissions, which may exhibit some seasonal patterns. The core nature of infusion therapy, vascular access, and vital care products suggests a relatively consistent demand driven by ongoing patient care needs. The company's forward-looking statements acknowledge risks such as decreased demand for products and changes in product mix. The IV equipment market, in which ICU Medical operates, is segmented into various products like IV catheters, infusion pumps, and needle-free connectors, with needle-free connectors and extension sets being a fast-growing segment in 2025 due to safety and ease of use.

ICU Medical, Inc. specializes in infusion therapy, vascular access, and vital care applications. The company operates within the Healthcare sector and the Medical Instruments & Supplies industry. ICU Medical has grown significantly through strategic acquisitions, including Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. ICU Medical's major products are categorized into three reporting segments: consumables, infusion systems, and vital care. Infusion Therapy Products include needlefree products, catheter patency devices, closed system transfer devices for hazardous drugs, needle-free connectors, non-coring needles and disinfection caps. IV Therapy and Diluents encompass solutions like sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, mannitol, and sterile water. Irrigation Solutions include sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, and sorbitol-mannitol irrigation. Infusion Pumps and Software feature products such as Plum 360 and Plum Duo infusion pumps, ambulatory and syringe infusion hardware, and IV medication safety software. Vascular Access Products include peripheral IV catheters and other related devices. Vital Care Products cover hemodynamic monitoring products, anesthesia systems and devices, breathing circuits, ventilation, respiratory, specialty airway products, and temperature management solutions. The company also offers professional services.

ICU Medical, Inc. has a global presence, with approximately 15,000 employees in over 35 countries as of December 31, 2024. The company's operations are primarily US-focused, generating over 60% of its sales domestically. Key geographic markets include the U.S., Europe, Asia-Pacific, the Middle East and Africa, and other foreign countries.

In 2014, Forbes Magazine named ICU Medical one of the "100 Most Trustworthy Companies in America". MarketBeat reports that ICU Medical scored higher than 62% of companies evaluated and ranked 390th out of 872 stocks in the medical sector. An event that could have impacted ICU Medical's reputation in the past year is the FDA identifying a recall of its Plum Duo as a serious type in September 2025.

ICU Medical, Inc. has a significant institutional ownership, with 543 institutional owners and shareholders holding a total of 34,500,167 shares. Major institutional owners include BlackRock, Inc., The Vanguard Group, Inc., Janus Henderson Group Plc, Fuller & Thaler Asset Management, Inc., Millennium Management LLC, State Street Corp, Dimensional Fund Advisors Lp, and Schroder Investment Management North America Inc. Individual owners include company insiders such as George A. Lopez (founder), Vivek Jain (CEO), Daniel Woolson, David C. Greenberg, Christian B. Voigtlander, Virginia Ruth Sanzone, Elisha W. Finney, and Ben Sousa.